Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trial

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLLПодробнее

Ongoing trials investigating the efficacy of pirtobrutinib in CLLПодробнее

Insights into the BRUIN CLL-322 trialПодробнее

Extensions of BRUIN investigating pirtobrutinib combinations for time-limited CLL treatmentПодробнее

BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLLПодробнее

Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN studyПодробнее

Some insights into BRUIN CLL-322: a trial in progressПодробнее

Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCLПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Phase I/II BRUIN update: efficacy of pirtobrutinib in R/R Waldenström's macroglobulinemiaПодробнее

Pirtobrutinib: The next generation of BTK inhibitorsПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

Pirtobrutinib resistance in CLL: early findingsПодробнее

Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCLПодробнее

Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trialПодробнее

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

CLL: Long-term updates on ibrutinib and idelalisibПодробнее